Veradigm Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Veradigm'in gelirinin yıllık 8.5% oranında azalacağı tahmin edilirken, yıllık kazancının yıllık 10.3% oranında artması beklenmektedir. EPS'nin yılda 3.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 3.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

10.3%

Kazanç büyüme oranı

3.5%

EPS büyüme oranı

Healthcare Services kazanç büyümesi	30.3%
Gelir büyüme oranı	-8.5%
Gelecekteki özkaynak getirisi	3.1%
Analist kapsamı	Low
Son güncelleme	12 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Veradigm Inc. (NASDAQ:MDRX) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 22

These 4 Measures Indicate That Veradigm (NASDAQ:MDRX) Is Using Debt Reasonably Well

Jan 04

Returns Are Gaining Momentum At Allscripts Healthcare Solutions (NASDAQ:MDRX)

Dec 03

Allscripts Healthcare reaffirms 2022 financial guidance; shares fall 2%

Sep 28

Should You Think About Buying Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Now?

Sep 17

Investors Will Want Allscripts Healthcare Solutions' (NASDAQ:MDRX) Growth In ROCE To Persist

Aug 24

We Think Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Taking Some Risk With Its Debt

Jul 31

Is Now An Opportune Moment To Examine Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX)?

Jun 15

We Like These Underlying Return On Capital Trends At Allscripts Healthcare Solutions (NASDAQ:MDRX)

May 03

Kazanç ve Gelir Büyüme Tahminleri

OTCPK:MDRX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	710	60	84	134	1
12/31/2025	677	43	60	102	2
12/31/2024	650	32	27	61	3
12/31/2023	626	54	84	117	3
12/31/2022	617	-4	N/A	N/A	2
9/30/2022	1,529	116	82	161	N/A
6/30/2022	1,522	125	107	189	N/A
3/31/2022	1,512	148	-91	-11	N/A
12/31/2021	1,503	134	-154	-75	N/A
9/30/2021	806	-14	-373	-319	N/A
6/30/2021	1,027	-48	-388	-322	N/A
3/31/2021	1,255	-96	-183	-98	N/A
12/31/2020	1,503	-133	-212	-107	N/A
9/30/2020	1,428	-143	-15	84	N/A
6/30/2020	1,507	-134	-44	67	N/A
3/31/2020	1,582	-263	-79	37	N/A
12/31/2019	1,633	-238	-74	46	N/A
9/30/2019	1,763	-197	-119	20	N/A
6/30/2019	1,751	-203	-138	-1	N/A
3/31/2019	1,748	34	-129	15	N/A
12/31/2018	1,618	-39	-66	68	N/A
9/30/2018	1,516	70	73	188	N/A
6/30/2018	1,533	54	105	237	N/A
3/31/2018	1,518	-187	120	262	N/A
12/31/2017	1,498	-183	122	279	N/A
9/30/2017	1,714	-210	67	257	N/A
6/30/2017	1,657	-191	65	246	N/A
3/31/2017	1,618	-48	105	269	N/A
12/31/2016	1,386	31	145	269	N/A
9/30/2016	1,470	-2	153	268	N/A
6/30/2016	1,432	3	N/A	255	N/A
3/31/2016	1,397	10	N/A	229	N/A
12/31/2015	1,386	-2	N/A	212	N/A
9/30/2015	1,382	-21	N/A	180	N/A
6/30/2015	1,373	-41	N/A	154	N/A
3/31/2015	1,372	-56	N/A	141	N/A
12/31/2014	1,378	-66	N/A	103	N/A
9/30/2014	1,388	-85	N/A	70	N/A
6/30/2014	1,373	-108	N/A	68	N/A
3/31/2014	1,366	-113	N/A	63	N/A
12/31/2013	1,373	-104	N/A	81	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MDRX 'nin tahmini kazanç büyümesi (yıllık 10.3% ) tasarruf oranının ( 2.6% ) üzerindedir.

Kazançlar ve Piyasa: MDRX şirketinin kazançlarının (yıllık 10.3% ) US pazarından (yıllık 15.3% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: MDRX şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: MDRX şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi bekleniyor (yılda -8.5% ).

Yüksek Büyüme Geliri: MDRX şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -8.5% ).

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MDRX 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 3.1 %).

Veradigm Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Veradigm Inc. Is Reaffirms Earnings Guidance for Fiscal 2024

Veradigm Inc. Provides Earnings Guidance for the Fiscal Year 2024

Price target decreased by 12% to US$14.33

Veradigm Inc. Revises Earnings Guidance for the Fiscal 2023

Veradigm Inc. Provides Revenue Guidance for the Fiscal Year 2023

Price target decreased by 7.1% to US$19.19

Recent updates

Veradigm Inc. announced delayed 10-Q filing

McKesson, Oracle, Thoma Bravo Reportedly Among Finalists to Acquire Veradigm

Veradigm Inc. announced delayed 10-Q filing

Holmusk and Veradigm Reach New Data Enrichment Milestone in Strategic Collaboration

Veradigm Inc. Is Reaffirms Earnings Guidance for Fiscal 2024

Veradigm Inc. Announces Interim Chief Executive Officer Changes

Veradigm Inc. announced delayed 10-Q filing

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Notify the Nasdaq's Determination to Delist Veradigm's Securities from Listing

Veradigm Inc. Provides Earnings Guidance for the Fiscal Year 2024

Veradigm Inc. (OTCPK:MDRX) completed the acquisition of Cascade Bio, Inc

Veradigm Inc. announced delayed annual 10-K filing

Veradigm Inc.(OTCPK:MDRX) dropped from NASDAQ Composite Index

Veradigm Receives Expected Delisting Notice from Nasdaq

Investor sentiment deteriorates as stock falls 18%

Veradigm Inc. signed a definitive agreement to acquire Cascade Bio, Inc.

Veradigm (NASDAQ:MDRX) Is Doing The Right Things To Multiply Its Share Price

Price target decreased by 12% to US$14.33

Veradigm Inc. Revises Earnings Guidance for the Fiscal 2023

Robbins Geller Rudman & Dowd LLP Files Amended Class Action Lawsuit Against Veradigm Inc

Nasdaq Hearings Panel Grants Veradigm's Request for Continued Listing on the Nasdaq Capital Market, Subject to Demonstrating Compliance with Nasdaq Listing Rule 5250(C)(1) on or Before February 27, 2024

Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Filed Against Veradigm Inc

Veradigm Inc. to Enhance Independent Practice Financial Management with AI for Practice Fusion Billing Services

Veradigm Inc. Announces CEO Changes

Veradigm Inc. Announces CEO Changes

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Veradigm Inc

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Veradigm Inc

Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q

Veradigm Inc. announced delayed 10-Q filing

Veradigm (NASDAQ:MDRX) Might Have The Makings Of A Multi-Bagger

Veradigm to Simplify Patient Payment Journey with Veradigm Intelligent Payments

Veradigm Inc. Announces Receipt of Nasdaq Stay Extension

Veradigm Inc. Announces Receipt of Nasdaq Delisting Notice and Intent to Appeal

Veradigm Inc. Provides Revenue Guidance for the Fiscal Year 2023

Veradigm Inc. announced delayed 10-Q filing

Veradigm Receives Approval from Nasdaq Regarding its Plan to Regain Compliance with Nasdaq Listing Rule 5250(c)(1)

Veradigm Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing

Veradigm Inc. announced delayed 10-Q filing

Price target decreased by 7.1% to US$19.19

Price target decreased by 9.1% to US$20.07

Veradigm's (NASDAQ:MDRX) Returns On Capital Are Heading Higher

Investor sentiment deteriorates as stock falls 15%

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Is It Too Late To Consider Buying Veradigm Inc. (NASDAQ:MDRX)?

Consensus EPS estimates fall by 11%

Veradigm Inc. (NASDAQ:MDRX) Shares Could Be 47% Below Their Intrinsic Value Estimate

Veradigm Inc. to Report Q4, 2022 Results on Feb 23, 2023

LeanTaaS Inc. acquired Hospital IQ, Inc.

These 4 Measures Indicate That Veradigm (NASDAQ:MDRX) Is Using Debt Reasonably Well

Insider notifies of intention to sell stock

Independent Director recently sold US$797k worth of stock

Returns Are Gaining Momentum At Allscripts Healthcare Solutions (NASDAQ:MDRX)

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Third quarter 2022 earnings: EPS misses analyst expectations

Allscripts Healthcare Solutions, Inc. Provides Revenue Guidance for the Year 2022

Allscripts Healthcare Solutions, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Allscripts Healthcare reaffirms 2022 financial guidance; shares fall 2%

Should You Think About Buying Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Now?

Chief Financial Officer recently sold US$116k worth of stock

Chief Financial Officer notifies of intention to sell stock

Investors Will Want Allscripts Healthcare Solutions' (NASDAQ:MDRX) Growth In ROCE To Persist

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer recently sold US$70k worth of stock

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: US$0.028 (vs US$0.16 in 2Q 2021)

We Think Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Taking Some Risk With Its Debt